GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biophytis ALBPS.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

0.04

+5.90%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2024

Net income

−€10.4m

FY2015FY2024

Free cash flow

−€17.8m

FY2015FY2024

Shareholders' equity

−€9.7m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Gross profit−€298,000−€803,000−€484,000−€311,000−€280,000−€262,000−€227,000−€204,000−€167,000−€65,000
Research and development€4.5m€10.4m€16.0m€19.7m€9.9m€9.1m€9.5m€7.0m€5.1m€1.6m
Operating income−€8.5m−€14.3m−€23.3m−€26.8m−€13.9m−€15.7m−€13.9m−€9.9m−€7.9m−€3.1m
Net income−€10.4m−€17.0m−€24.2m−€33.5m−€25.5m−€18.9m−€14.0m−€11.4m−€8.0m−€5.2m
Diluted earnings per share-1.51-8.98-47.98-106.53-123.39-0.79-420.03-404.54-513.16-351.14

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets€6.9m€12.0m€22.0m€36.3m€27.2m€17.7m€21.9m€25.9m€8.4m€13.5m
Cash and short-term investments€78,000€5.6m€11.1m€25.2m€18.3m€6.8m€14.4m€19.9m€3.1m€9.4m
Total liabilities€16.6m€15.8m€23.9m€30.6m€20.4m€25.2m€14.9m€4.8m€3.9m€1.9m
Debt€9.8m€8.3m€14.6m€17.6m€9.1m€15.2m€8.2m€1.0m€1.1m€802,792
Shareholders' equity−€9.7m−€3.9m−€1.9m€5.8m€2.3m−€7.5m€7.0m€21.2m€4.5m€11.7m
Shares outstanding7m2m1m0m0m24m0m0m0m0m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−€8.6m−€12.9m−€19.0m−€23.8m−€9.9m−€15.3m−€12.1m−€8.7m−€6.6m−€3.2m
Capital spending−€9.2m−€220,000−€141,000−€344,000−€214,000−€282,000−€113,000−€128,000−€129,000−€6,190
Free cash flow−€17.8m−€13.1m−€19.1m−€24.1m−€10.1m−€15.6m−€12.2m−€8.9m−€6.8m−€3.2m

Latest quarters

By quarter end

Sept 2025Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Gross profit−€192,984−€207,000−€150,000−€148,000—−€1.3m—−€300,000
Operating income−€4.1m−€4.4m−€4.1m−€4.4m−€2.2m−€7.8m−€3.9m−€6.5m
Net income−€3.2m−€3.5m−€4.6m−€5.8m−€2.9m−€9.3m−€4.6m−€7.8m
Diluted earnings per share-0.17-0.18-0.66-0.84-0.42-4.88-2.44-4.09
Cash from operations−€3.0m−€3.0m−€2.0m−€6.0m—−€4.0m——
Capital spending−€3.0m−€3.0m——————
Free cash flow−€6.0m−€6.0m——————
Total assets€6.6m€6.6m€6.9m€8.7m€8.7m€11.9m€12.0m€14.6m
Cash and short-term investments€1.2m€1.2m€78,000€2.2m€2.2m€5.6m€5.6m€6.2m
Debt€4.6m€7.8m€9.8m€9.7m€8.9m€8.3m€5.0m€10.1m
Shareholders' equity−€7.8m−€7.8m−€9.7m−€6.4m−€6.4m−€3.9m−€3.9m−€3.3m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-31.8%-11.5%28.8%
Net income-32.4%-11.3%30.8%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-0.3-0.2-0.4-1.9-3.0-36.3-0.6-1.7-1.1-4.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 400-to-1 reverse split · 3 May 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.